Vascular endothelial growth factor and diabetic complications

Progress in Retinal and Eye Research

Volumn 27, Issue 6, 2008, Pages 608-621

  Wirostko, Barbara ^a   Wong, Tien Y ^b   Simó, Rafael ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Angiogenesis inhibitors; Cardiovascular disease; Diabetes mellitus; Diabetic angiopathies; Diabetic retinopathy; Microvascular disease; Stroke; Vascular endothelial growth factor; Vascular endothelial growth factor receptors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; MESSENGER RNA; PEGAPTANIB; PLASMID VECTOR; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOMYOPATHY; CELL ACTIVITY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE MARKER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FEEDBACK SYSTEM; GENE DISRUPTION; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LASER COAGULATION; LIMB ISCHEMIA; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEINURIA; RETINA NEOVASCULARIZATION; REVIEW; SPINAL CORD INJURY; STROKE; UNCERTAINTY; WOUND HEALING;

ANGIOGENESIS INHIBITORS; DIABETES COMPLICATIONS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55849126672     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2008.09.002     Document Type: Review

References (157)

1. Adamis A.P., Altaweel M., Bressler N.M., Cunningham Jr. E.T., Davis M.D., Goldbaum M., Gonzales C., Guyer D.R., Barrett K., and Patel M. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (2006) 23-28
2. Adler E.M., Gough N.R., and Ray L.B. 2006: signaling breakthroughs of the year. Sci. STKE. (2007) 2007: eg1
3. Aicher A., Zeiher A.M., and Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 45 (2005) 321-325
4. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., and Park J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J Med. 331 (1994) 1480-1487
5. Akhavani M.A., Larsen H., and Paleolog E. Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand. J. Rheumatol. 36 (2007) 83-90
6. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., Kleinman M.E., Caldwell R.B., Lin Q., Ogura Y., Orecchia A., Samuelson D.A., Agnew D.W., St, Leger J., Green W.R., Mahasreshti P.J., Curiel D.T., Kwan D., Marsh H., Ikeda S., Leiper L.J., Collinson J.M., Bogdanovich S., Khurana T.S., Shibuya M., Baldwin M.E., Ferrara N., Gerber H.P., De F.S., Witta J., Baffi J.Z., Raisler B.J., and Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443 (2006) 993-997
7. Anonymous, 2008. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap-Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R.D. 9: 261-269.
8. Apte R.S., Modi M., Masonson H., Patel M., Whitfield L., and Adamis A.P. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114 (2007) 1702-1712
9. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., and Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18 (1999) 3964-3972
10. Asai J., Takenaka H., Katoh N., and Kishimoto S. Dibutyryl cAMP influences endothelial progenitor cell recruitment during wound neovascularization. J. Invest. Dermatol. 126 (2006) 1159-1167
11. Asselbergs F.W., de Boer R.A., Diercks G.F., Langeveld B., Tio R.A., de Jong P.E., van Veldhuisen D.J., and van Gilst W.H. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria?. Int. J. Cardiol. 93 (2004) 211-215
12. Baelde H.J., Eikmans M., Doran P.P., Lappin D.W., de H.E., and Bruijn J.A. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am. J. Kidney Dis. 43 (2004) 636-650
13. Baelde H.J., Eikmans M., Lappin D.W., Doran P.P., Hohenadel D., Brinkkoetter P.T., van der Woude F.J., Waldherr R., Rabelink T.J., de H.E., and Bruijn J.A. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 71 (2007) 637-645
14. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Ezzat M.K., and Singh R.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114 (2007) 2179-2182
15. Balestrieri M.L., Rienzo M., Felice F., Rossiello R., Grimaldi V., Milone L., Casamassimi A., Servillo L., Farzati B., Giovane A., and Napoli C. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim. Biophys. Acta. 1784 (2008) 936-945
16. Bardal S., Misurski D., Qiu X., Desai K., and McNeill J.R. Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat. Diabetologia 49 (2006) 811-818
17. Bates D.O., and Harper S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vasc. Pharmacol. 39 (2002) 225-237
18. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
19. Blann A.D., Belgore F.M., McCollum C.N., Silverman S., Lip P.L., and Lip G.Y. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin. Sci. (Lond.) 102 (2002) 187-194
20. Bortoloso E., Del P.D., Dalla V.M., Gambaro G., Saller A., Antonucci F., Baggio B., Anglani F., and Fioretto P. Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur. J. Endocrinol. 150 (2004) 799-807
21. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., and Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1432-1444
22. Burgos R., Simó R., Audi L., Mateo C., Mesa J., Garcia-Ramirez M., and Carrascosa A. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 40 (1997) 1107-1109
23. Caldwell R.B., Bartoli M., Behzadian M.A., El-Remessy A.E., Al-Shabrawey M., Platt D.H., and Caldwell R.W. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab. Res. Rev. 19 (2003) 442-455
24. Carmeliet P., and Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 13 (2002) 39-53
25. Centers for Disease Control and Prevention. Incidence of end-stage renal disease among persons with diabetes-United States, 1990-2002. MMWR Morb. Mortal. Wkly. Rep. 54 (2005) 1097-1100
26. Chakrabarti S., Cukiernik M., Hileeto D., Evans T., and Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab. Res. Rev. 16 (2000) 393-407
27. Chattopadhyay M., Krisky D., Wolfe D., Glorioso J.C., Mata M., and Fink D.J. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 12 (2005) 1377-1384
28. Chaturvedi N., Fuller J.H., Pokras F., Rottiers R., Papazoglou N., and Aiello L.P. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet. Med. 18 (2001) 288-294
29. Cheung N., Bluemke D.A., Klein R., Sharrett A.R., Islam F.M., Cotch M.F., Klein B.E., Criqui M.H., and Wong T.Y. Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J. Am. Coll. Cardiol. 50 (2007) 48-55
30. Cheung N., Rogers S., Couper D.J., Klein R., Sharrett A.R., and Wong T.Y. Is diabetic retinopathy an independent risk factor for ischemic stroke?. Stroke 38 (2007) 398-401
31. Cheung N., Wang J.J., Klein R., Couper D.J., Sharrett A.R., and Wong T.Y. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 30 (2007) 1742-1746
32. Cheung N., Wang J.J., Rogers S.L., Brancati F., Klein R., Sharrett A.R., and Wong T.Y. Diabetic retinopathy and risk of heart failure. J. Am. Coll. Cardiol. 51 (2008) 1573-1578
33. Cheung N., and Wong T.Y. Diabetic retinopathy and systemic vascular complications. Prog. Retin. Eye Res. 27 (2008) 161-176
34. Chin B.S., Blann A.D., Gibbs C.R., Chung N.A., Conway D.G., and Lip G.Y. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur. J. Clin. Invest. 33 (2003) 941-948
35. Choi J.S., Kim K.B., Han W., Kim D.S., Park J.S., Lee J.J., and Lee D.S. Efficacy of therapeutic angiogenesis by intramyocardial injection of pCK-VEGF165 in pigs. Ann. Thorac. Surg. 82 (2006) 679-686
36. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., Suzuma K., Bowling N.L., Vlahos C.J., Aiello L.P., and King G.L. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105 (2002) 373-379
37. Chung A.W., Hsiang Y.N., Matzke L.A., McManus B.M., van B.C., and Okon E.B. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ. Res. 99 (2006) 140-148
38. Chung N.A., Lydakis C., Belgore F., Blann A.D., and Lip G.Y. Angiogenesis in myocardial infarction. An acute or chronic process?. Eur. Heart J. 23 (2002) 1604-1608
39. Chung N.A., Lydakis C., Belgore F., Li-Saw-Hee F.L., Blann A.D., and Lip G.Y. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 89 (2003) 1411-1415
40. Cohen A., Lim K.H., Lee Y., Rana S., Karumanchi S.A., and Brown F. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care 30 (2007) 375-377
41. Congdon N.G., Friedman D.S., and Lietman T. Important causes of visual impairment in the world today. JAMA 290 (2003) 2057-2060
42. Csaky, K.G., 2007. Pharmacokinetics of Bevacizumab. American Academy of Ophthalmology, Retinal subspecialty, oral presentation. November 9-11, New Orleans, LA.
43. Csaky K.G., Richman E.A., and Ferris III F.L. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest. Ophthalmol. Vis. Sci. 49 (2008) 479-489
44. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., and Schwartz S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
45. Drolet D.W., Nelson J., Tucker C.E., Zack P.M., Nixon K., Bolin R., Judkins M.B., Farmer J.A., Wolf J.L., Gill S.C., and Bendele R.A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17 (2000) 1503-1510
46. Duh E., and Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48 (1999) 1899-1906
47. Edwards M.S., Wilson D.B., Craven T.E., Stafford J., Fried L.F., Wong T.Y., Klein R., Burke G.L., and Hansen K.J. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study. Am. J. Kidney Dis. 46 (2005) 214-224
48. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., and Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111 (2003) 707-716
49. Fadini G.P., Sartore S., Schiavon M., Albiero M., Baesso I., Cabrelle A., Agostini C., and Avogaro A. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 49 (2006) 3075-3084
50. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 366 (2005) 1736-1743
51. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
52. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280 (2001) C1358-C1366
53. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
54. Flyvbjerg A., Khatir D.S., Jensen L.J., gnaes-Hansen F., Gronbaek H., and Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr. Pharm. Des. 10 (2004) 3385-3394
55. Funatsu H., Yamashita H., Nakamura S., Mimura T., Eguchi S., Noma H., and Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113 (2006) 294-301
56. Funatsu H., Yamashita H., Noma H., Mimura T., Nakamura S., Sakata K., and Hori S. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch. Clin. Exp. Ophthalmol 243 (2005) 3-8
57. Gaudreault J., Fei D., Rusit J., Suboc P., and Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46 (2005) 726-733
58. Gehlbach P., Demetriades A.M., Yamamoto S., Deering T., Xiao W.H., Duh E.J., Yang H.S., Lai H., Kovesdi I., Carrion M., Wei L., and Campochiaro P.A. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum. Gene Ther. 14 (2003) 129-141
59. George J., Goldstein E., Abashidze S., Deutsch V., Shmilovich H., Finkelstein A., Herz I., Miller H., and Keren G. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur. Heart J. 25 (2004) 1003-1008
60. Ghetie V., and Ward E.S. Transcytosis and catabolism of antibody. Immunol. Res. 25 (2002) 97-113
61. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
62. Grosso A., Veglio F., Porta M., Grignolo F.M., and Wong T.Y. Hypertensive retinopathy revisited: some answers, more questions. Br. J. Ophthalmol. 89 (2005) 1646-1654
63. Hayashi T., Abe K., and Itoyama Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J. Cereb. Blood Flow Metab. 18 (1998) 887-895
64. Heier J.S., Boyer D.S., Ciulla T.A., Ferrone P.J., Jumper J.M., Gentile R.C., Kotlovker D., Chung C.Y., and Kim R.Y. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch. Ophthalmol. 124 (2006) 1532-1542
65. Heilmann C.A., Attmann T., Thiem A., Haffner E., Beyersdorf F., and Lutter G. Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia. Eur. J. Cardiothorac. Surg. 24 (2003) 785-793
66. Hernández C., Burgos R., Canton A., Garcia-Arumi J., Segura R.M., and Simó R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care 24 (2001) 516-521
67. Hernández C., and Simó R. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin. Invest. Drugs 16 (2007) 1209-1226
68. Hohenstein B., Hausknecht B., Boehmer K., Riess R., Brekken R.A., and Hugo C.P. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 69 (2006) 1654-1661
69. Humpert P.M., Eichler H., Lammert A., Hammes H.P., Nawroth P.P., and Bierhaus A. Adult vascular progenitor cells and tissue regeneration in metabolic syndrome. Vasa 34 (2005) 73-78 80
70. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J.W., Gragoudas E.S., Ng Y.S., D'Amore P.A., Shima D.T., and Adamis A.P. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198 (2003) 483-489
71. Issa R., Krupinski J., Bujny T., Kumar S., Kaluza J., and Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab. Invest. 79 (1999) 417-425
72. Jeerakathil T., Johnson J.A., Simpson S.H., and Majumdar S.R. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study 2. Stroke 38 (2007) 1739-1743
73. Kaiser P.K. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am. J. Ophthalmol. 142 (2006) 660-668
74. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96 (2007) 1788-1795
75. Kanesaki Y., Suzuki D., Uehara G., Toyoda M., Katoh T., Sakai H., and Watanabe T. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis. 45 (2005) 288-294
76. Katavetin P., Miyata T., Inagi R., Tanaka T., Sassa R., Ingelfinger J.R., Fujita T., and Nangaku M. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J. Am. Soc. Nephrol. 17 (2006) 1405-1413
77. Kaya D., Gursoy-Ozdemir Y., Yemisci M., Tuncer N., Aktan S., and Dalkara T. VEGF protects brain against focal ischemia without increasing blood-brain permeability when administered intracerebroventricularly. J. Cereb. Blood Flow Metab. 25 (2005) 1111-1118
78. Kim H., Fariss R.N., Zhang C., Robinson S.B., Thill M., and Csaky K.G. Mapping of the neonatal Fc receptor in the rodent eye. Invest. Ophthalmol. Vis. Sci. 49 (2008) 2025-2029
79. Kim H., Lee J.M., Park J.S., Jo S.A., Kim Y.O., Kim C.W., and Jo I. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem. Biophys. Res. Commun. 372 (2008) 243-248
80. Kim N.H., Kim K.B., Kim D.L., Kim S.G., Choi K.M., Baik S.H., Choi D.S., Kang Y.S., Han S.Y., Han K.H., Ji Y.H., and Cha D.R. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet. Med. 21 (2004) 545-551
81. Kim N.H., Oh J.H., Seo J.A., Lee K.W., Kim S.G., Choi K.M., Baik S.H., Choi D.S., Kang Y.S., Han S.Y., Han K.H., Ji Y.H., and Cha D.R. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 67 (2005) 167-177
82. Kimura R., Nakase H., Tamaki R., and Sakaki T. Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction. Stroke 36 (2005) 1259-1263
83. Kolsut P., Malecki M., Zelazny P., Teresinska A., Firek B., Janik P., and Religa Z. Gene therapy of coronary artery disease with phvegf165-early outcome. Kardiol. Pol. 59 (2003) 373-384
84. Konopatskaya O., Churchill A.J., Harper S.J., Bates D.O., and Gardiner T.A. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis. 12 (2006) 626-632
85. Krentz A.J., Clough G., and Byrne C.D. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes. Metab. 9 (2007) 781-791
86. Kusumanto Y.H., van W., V, Mulder N.H., Smit A.J., van den Dungen J.J., Hooymans J.M., Sluiter W.J., Tio R.A., Quax P.H., Gans R.O., Dullaart R.P., and Hospers G.A. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 17 (2006) 683-691
87. Lamoreaux W.J., Fitzgerald M.E., Reiner A., Hasty K.A., and Charles S.T. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc. Res. 55 (1998) 29-42
88. Lee E.Y., Chung C.H., Kim J.H., Joung H.J., and Hong S.Y. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes. Nephrol. Dial. Transplant. 21 (2006) 1496-1503
89. Lei L., Zhou R., Zheng W., Christensen L.P., Weiss R.M., and Tomanek R.J. Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart. Circulation 110 (2004) 796-802
90. Lerman O.Z., Galiano R.D., Armour M., Levine J.P., and Gurtner G.C. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am. J. Pathol. 162 (2003) 303-312
91. Li Y., Lu Z.Y., Ogle M., and Wei L. Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice. Neurochem. Res. 32 (2007) 2132-2141
92. Liao D., Wong T.Y., Klein R., Jones D., Hubbard L., and Sharrett A.R. Relationship between carotid artery stiffness and retinal arteriolar narrowing in healthy middle-aged persons. Stroke 35 (2004) 837-842
93. Lip P.L., Belgore F., Blann A.D., Hope-Ross M.W., Gibson J.M., and Lip G.Y. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest. Ophthalmol. Vis. Sci. 41 (2000) 2115-2119
94. Lip P.L., Chatterjee S., Caine G.J., Hope-Ross M., Gibson J., Blann A.D., and Lip G.Y. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br. J. Ophthalmol. 88 (2004) 1543-1546
95. Luttun A., and Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?. J. Clin. Invest. 111 (2003) 600-602
96. Maruyama K., Asai J., Ii M., Thorne T., Losordo D.W., and D'Amore P.A. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am. J. Pathol. 170 (2007) 1178-1191
97. Melder R.J., Koenig G.C., Witwer B.P., Safabakhsh N., Munn L.L., and Jain R.K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2 (1996) 992-997
98. Michel J.B. Role of endothelial nitric oxide in the regulation of the vasomotor system. Pathol. Biol. (Paris) 46 (1998) 181-189 in French
99. Michowitz Y., Goldstein E., Wexler D., Sheps D., Keren G., and George J. Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart 93 (2007) 1046-1050
100. Mitchell P., Wang J.J., Wong T.Y., Smith W., Klein R., and Leeder S.R. Retinal microvascular signs and risk of stroke and stroke mortality. Neurology 65 (2005) 1005-1009
101. Morbidelli L., Donnini S., and Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr. Pharm. Des. 9 (2003) 521-530
102. Moss S.E., Klein R., Klein B.E., and Wong T.Y. Retinal vascular changes and 20-year incidence of lower extremity amputations in a cohort with diabetes. Arch. Intern. Med 163 (2003) 2505-2510
103. Murakami T., Arai M., Sunada Y., and Nakamura A. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J. Gene Med 8 (2006) 773-781
104. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am. J. Physiol. Renal Physiol. 292 (2007) F1665-F1672
105. Nakagawa T., Sato W., Sautin Y.Y., Glushakova O., Croker B., Atkinson M.A., Tisher C.C., and Johnson R.J. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J. Am. Soc. Nephrol. 17 (2006) 736-745
106. Nguyen T.T., Wang J.J., and Wong T.Y. Retinal vascular changes in pre-diabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 30 (2007) 2708-2715
107. Nguyen T.T., and Wong T.Y. Retinal vascular manifestations of metabolic disorders. Trends Endocrinol. Metab 17 (2006) 262-268
108. Nissen N.N., Polverini P.J., Koch A.E., Volin M.V., Gamelli R.L., and DiPietro L.A. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 152 (1998) 1445-1452
109. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7 (2006) 359-371
110. Pandya N.M., Dhalla N.S., and Santani D.D. Angiogenesis-a new target for future therapy. Vascul. Pharmacol. 44 (2006) 265-274
111. Parenti A., Morbidelli L., Cui X.L., Douglas J.G., Hood J.D., Granger H.J., Ledda F., and Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 273 (1998) 4220-4226
112. Patel J.I., Tombran-Tink J., Hykin P.G., Gregor Z.J., and Cree I.A. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp. Eye Res. 82 (2006) 798-806
113. Pepper M.S., Ferrara N., Orci L., and Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181 (1991) 902-906
114. Perrin R.M., Konopatskaya O., Qiu Y., Harper S., Bates D.O., and Churchill A.J. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48 (2005) 2422-2427
115. Price S.A., Dent C., Duran-Jimenez B., Liang Y., Zhang L., Rebar E.J., Case C.C., Gregory P.D., Martin T.J., Spratt S.K., and Tomlinson D.R. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 55 (2006) 1847-1854
116. Raab S., and Plate K.H. Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol. (Berl.) 113 (2007) 607-626
117. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., and Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med 355 (2006) 1419-1431
118. Saaristo A., Tammela T., Farkkila A., Karkkainen M., Suominen E., Yla-Herttuala S., and Alitalo K. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am. J. Pathol 169 (2006) 1080-1087
119. Sang D.N., and D'Amore P.A. Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?. Diabetologia 51 (2008) 1570-1573
120. Santilli F., Spagnoli A., Mohn A., Tumini S., Verrotti A., Cipollone F., Mezzetti A., and Chiarelli F. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J. Clin. Endocrinol. Metab 86 (2001) 3871-3876
121. Sasso F.C., Torella D., Carbonara O., Ellison G.M., Torella M., Scardone M., Marra C., Nasti R., Marfella R., Cozzolino D., Indolfi C., Cotrufo M., Torella R., and Salvatore T. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J. Am. Coll. Cardiol 46 (2005) 827-834
122. Schlachetzki F., Zhu C., and Pardridge W.M. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem 81 (2002) 203-206
123. Schmidt-Lucke C., Rossig L., Fichtlscherer S., Vasa M., Britten M., Kamper U., Dimmeler S., and Zeiher A.M. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 (2005) 2981-2987
124. Schrijvers B.F., Flyvbjerg A., and De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65 (2004) 2003-2017
125. Schrijvers B.F., Flyvbjerg A., Tilton R.G., Lameire N.H., and De Vriese A.S. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol. Dial. Transplant 21 (2006) 324-329
126. Semenza G.L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med 54 (2003) 17-28
127. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39 (2006) 469-478
128. Silvestre J.S. Vascular progenitor cells and diabetes: role in postischemic neovascularisation. Diabetes Metab. 34 Suppl. 1 (2008) S33-S36
129. Simó R., Carrasco E., Garcia-Ramirez M., and Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabetes Rev. 2 (2006) 71-98
130. Simó R., and Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51 (2008) 1574-1580
131. Simó R., Lecube A., Segura R.M., Garcia A.J., and Hernández C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol 134 (2002) 376-382
132. Spranger J., Hammes H.P., Preissner K.T., Schatz H., and Pfeiffer A.F. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 43 (2000) 1404-1407
133. Stokes K.Y., and Granger D.N. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia?. J. Physiol 562 (2005) 647-653
134. Storkebaum E., Lambrechts D., and Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26 (2004) 943-954
135. Suzuma I., Hata Y., Clermont A., Pokras F., Rook S.L., Suzuma K., Feener E.P., and Aiello L.P. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 50 (2001) 444-454
136. Takahashi H., and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond.) 109 (2005) 227-241
137. Tanaka Y., Katoh S., Hori S., Miura M., and Yamashita H. Vascular endothelial growth factor in diabetic retinopathy. Lancet 349 (1997) 1520
138. Tepper O.M., Capla J.M., Galiano R.D., Ceradini D.J., Callaghan M.J., Kleinman M.E., and Gurtner G.C. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 105 (2005) 1068-1077
139. Tsai W.C., Li Y.H., Huang Y.Y., Lin C.C., Chao T.H., and Chen J.H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin. Sci. (Lond.) 109 (2005) 39-43
140. Urbich C., and Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 67 (2005) 1672-1676
141. van Wijngaarden P., Coster D.J., and Williams K.A. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293 (2005) 1509-1513
142. Verheul H.M., and Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7 (2007) 475-485
143. Webb N.J., Bottomley M.J., Watson C.J., and Brenchley P.E. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin. Sci. (Lond.) 94 (1998) 395-404
144. Wong T.Y., Cheung N., Islam F.M., Klein R., Criqui M.H., Cotch M.F., Carr J.J., Klein B.E., and Sharrett A.R. Relation of retinopathy to coronary artery calcification: the multi-ethnic study of atherosclerosis. Am. J. Epidemiol 167 (2008) 51-58
145. Wong T.Y., Coresh J., Klein R., Muntner P., Couper D.J., Sharrett A.R., Klein B.E., Heiss G., Hubbard L.D., and Duncan B.B. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J. Am. Soc. Nephrol 15 (2004) 2469-2476
146. Wong T.Y., Duncan B.B., Golden S.H., Klein R., Couper D.J., Klein B.E., Hubbard L.D., Sharrett A.R., and Schmidt M.I. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2949-2954
147. Wong T.Y., Klein R., Couper D.J., Cooper L.S., Shahar E., Hubbard L.D., Wofford M.R., and Sharrett A.R. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 358 (2001) 1134-1140
148. Wong T.Y., Klein R., Nieto F.J., Klein B.E., Sharrett A.R., Meuer S.M., Hubbard L.D., and Tielsch J.M. Retinal microvascular abnormalities and 10-year cardiovascular mortality: a population-based case-control study. Ophthalmology 110 (2003) 933-940
149. Wong T.Y., Klein R., Sharrett A.R., Couper D.J., Klein B.E., Liao D.P., Hubbard L.D., and Mosley T.H. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 288 (2002) 67-74
150. Wong T.Y., Liew G., and Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 370 (2007) 204-206
151. Wong T.Y., Mosley Jr. T.H., Klein R., Klein B.E., Sharrett A.R., Couper D.J., and Hubbard L.D. Retinal microvascular changes and MRI signs of cerebral atrophy in healthy, middle-aged people. Neurology 61 (2003) 806-811
152. Wong T.Y., Rosamond W., Chang P.P., Couper D.J., Sharrett A.R., Hubbard L.D., Folsom A.R., and Klein R. Retinopathy and risk of congestive heart failure. JAMA 293 (2005) 63-69
153. Woolard J., Wang W.Y., Bevan H.S., Qiu Y., Morbidelli L., Pritchard-Jones R.O., Cui T.G., Sugiono M., Waine E., Perrin R., Foster R., Digby-Bell J., Shields J.D., Whittles C.E., Mushens R.E., Gillatt D.A., Ziche M., Harper S.J., and Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64 (2004) 7822-7835
154. Yang R., Thomas G.R., Bunting S., Ko A., Ferrara N., Keyt B., Ross J., and Jin H. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 27 (1996) 838-844
155. Yoon Y.S., Uchida S., Masuo O., Cejna M., Park J.S., Gwon H.C., Kirchmair R., Bahlman F., Walter D., Curry C., Hanley A., Isner J.M., and Losordo D.W. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111 (2005) 2073-2085
156. Zhu X., Wu S., Dahut W.L., and Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49 (2007) 186-193
157. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., and Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99 (1997) 2625-2634